At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 128 enrolled
Drug / intervention
Lanreotide Autogel® +1 moredrug
Likely dose
Lanreotide Autogel® 60mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, Prospective, Randomised, Open Label Study to Compare the Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg PR in Subjects With Active Acromegaly
In Brief
A Phase 3 clinical trial evaluating Lanreotide Autogel® and Lanreotide Acetate for Acromegaly. Completed, enrolled 128 participants across 10 sites.
Detailed Summary
The purpose is to compare the efficacy and safety of lanreotide autogel® 60mg, 90mg or 120mg with lanreotide 40mg PR in subjects with active acromegaly.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcromegaly
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartOct 2014
First PostedJul 2015
Primary CompletionNov 2016
Study CompletionFeb 2017
TodayJul 2026
First PostedJul 9, 2015
Enrollment StartOct 1, 2014
Primary CompletionNov 1, 2016
Study CompletionFeb 16, 2017
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 11.0 years ago
Interventions
Lanreotide Autogel®drug
Lanreotide Autogel 60mg, 90mg, and 120mg, pre-filled syringe, deep subcutaneous injection (provided as a supersaturated solution of lanreotide acetate).
Lanreotide Acetatedrug
Lanreotide PR 40mg white freeze-drying cake, 40mg/vial, deep subcutaneous injection (provided as a sterile injectable lyophilisate of lanreotide acetate).